European urology
Journal
Overview
publication venue for
-
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.
2020
-
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.
2017
-
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
2015
-
Guidelines for reporting of statistics in European Urology.
2014
-
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
2013
-
EAU guidelines on robotic and single-site surgery in urology.
2013
-
European guidelines on upper tract urothelial carcinomas: 2013 update.
2013
-
Guidelines on bladder cancer.
2002
-
Inverted urothelial papilloma: a lesion with malignant potential.
1988
-
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial..
84.
2023
-
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study..
83.
2023
-
Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer..
83.
2022
-
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer..
83.
2022
-
Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study..
82.
2022
-
Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound..
82.
2022
-
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy..
81.
2022
-
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021..
82.
2022
-
Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling..
82.
2022
-
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study..
80.
2021
-
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?.
80.
2021
-
Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study..
80.
2021
-
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma..
80.
2021
-
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial..
79.
2021
-
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel..
79.
2021
-
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring..
78.
2020
-
Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita..
78.
2020
-
Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer..
79.
2020
-
Infertile Men Have Higher Prostate-specific Antigen Values than Fertile Individuals of Comparable Age..
79.
2020
-
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma..
78.
2020
-
Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series..
78.
2020
-
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought..
78.
2020
-
Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature..
78.
2020
-
Retzius-sparing Robot-assisted Radical Prostatectomy Leads to Durable Improvement in Urinary Function and Quality of Life Versus Standard Robot-assisted Radical Prostatectomy Without Compromise on Oncologic Efficacy: Single-surgeon Series and Step-by-step Guide..
79.
2020
-
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics..
78.
2020
-
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer..
77.
2020
-
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study..
77.
2019
-
Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance..
77.
2019
-
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies..
77.
2019
-
Quality Indicators for Bladder Cancer Services: A Collaborative Review..
78.
2019
-
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights..
76.
2019
-
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect..
76.
2019
-
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract..
76.
2019
-
Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study..
76.
2019
-
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer..
76.
2018
-
Posterior, Anterior, and Periurethral Surgical Reconstruction of Urinary Continence Mechanisms in Robot-assisted Radical Prostatectomy: A Description and Video Compilation of Commonly Performed Surgical Techniques..
76.
2018
-
Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis..
75.
2018
-
External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis..
75.
2018
-
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy..
75.
2018
-
Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade..
75.
2018
-
Corrigendum re: "The Impact of Prostate Size, Median Lobe, and Prior Benign Prostatic Hyperplasia Intervention on Robot-Assisted Laparoscopic Prostatectomy: Technique and Outcomes" [Eur Urol 2011;59:595-603]..
74.
2018
-
Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes..
74.
2018
-
More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis..
74.
2018
-
Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review..
73.
2018
-
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study..
73.
2018
-
Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]..
73.
2018
-
Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series..
73.
2017
-
The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review..
73.
2017
-
Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies..
73.
2017
-
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results..
73.
2017
-
Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy..
73.
2017
-
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets..
72.
2017
-
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies..
72.
2017
-
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025..
72.
2017
-
Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition..
72.
2017
-
Local Therapy Improves Survival in Metastatic Prostate Cancer..
72.
2017
-
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302..
72.
2017
-
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma..
72.
2017
-
A Systematic Approach to Discussing Active Surveillance with Patients with Low-risk Prostate Cancer..
71.
2017
-
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer..
71.
2016
-
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma..
71.
2016
-
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)..
71.
2016
-
Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage..
71.
2016
-
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer..
71.
2016
-
Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series..
71.
2016
-
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study..
71.
2016
-
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302..
71.
2016
-
Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force..
71.
2016
-
When to Perform Karyotype Analysis in Infertile Men? Validation of the European Association of Urology Guidelines with the Proposal of a New Predictive Model..
70.
2016
-
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016..
71.
2016
-
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer..
70.
2016
-
Retraction notice to "Randomized Trial of Narrow-band Versus White-light Cystoscopy for Restaging (Second-look) Transurethral Resection of Bladder Tumors": Eur Urol 67 (2015) 605-608..
70.
2016
-
Retraction notice to "Reply from Author re: Peter C. Black. Narrowing the Cystoscopy Gap. Eur Urol 2015;67:609-10: A Better Transurethral Resection-Proved or Not!": Eur Urol 67 (2015) 610-611..
70.
2016
-
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition..
71.
2016
-
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition..
70.
2016
-
Lethal Prostate Cancer in the PLCO Cancer Screening Trial..
70.
2016
-
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort..
70.
2016
-
Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study..
70.
2016
-
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study..
71.
2016
-
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer..
70.
2016
-
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer..
70.
2016
-
Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study..
70.
2016
-
Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy..
70.
2016
-
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer..
70.
2016
-
Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer..
70.
2015
-
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies..
69.
2015
-
Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy..
69.
2015
-
PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2..
69.
2015
-
An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy..
69.
2015
-
Unexpected Long-term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-reported Outcomes Following Radical Prostatectomy..
68.
2015
-
Genomic Characterization of Upper Tract Urothelial Carcinoma..
68.
2015
-
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma..
69.
2015
-
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score..
69.
2015
-
Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer..
68.
2015
-
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men..
69.
2015
-
Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy..
68.
2015
-
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302..
68.
2015
-
Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium..
68.
2015
-
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort..
69.
2015
-
Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes..
69.
2015
-
Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death..
68.
2015
-
Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer..
68.
2015
-
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer..
68.
2015
-
Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?.
67.
2015
-
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study..
68.
2015
-
Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial..
67.
2014
-
Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer..
68.
2014
-
The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy..
67.
2014
-
Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy..
67.
2014
-
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer..
67.
2014
-
Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology..
67.
2014
-
Defining a standard set of patient-centered outcomes for men with localized prostate cancer..
67.
2014
-
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial..
67.
2014
-
The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men..
66.
2014
-
Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer..
68.
2014
-
Conditional survival after radical nephroureterectomy for upper tract carcinoma..
67.
2014
-
Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men..
67.
2014
-
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder..
67.
2014
-
Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors..
67.
2014
-
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients..
67.
2014
-
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301..
67.
2014
-
More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer..
67.
2014
-
Technique and outcomes of robot-assisted retroperitoneoscopic partial nephrectomy: a multicenter study..
66.
2014
-
Renal tumor contact surface area: a novel parameter for predicting complexity and outcomes of partial nephrectomy..
66.
2014
-
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)..
66.
2014
-
ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma..
66.
2014
-
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort..
67.
2014
-
Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control..
66.
2014
-
Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer..
66.
2014
-
Robotic partial nephrectomy with superselective versus main artery clamping: a retrospective comparison..
66.
2014
-
The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study..
66.
2014
-
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study..
66.
2014
-
Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort..
66.
2013
-
Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma..
66.
2013
-
Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy..
66.
2013
-
Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients..
66.
2013
-
A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients..
66.
2013
-
Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer..
65.
2013
-
Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT)..
65.
2013
-
Determinants of laparoscopic donor nephrectomy outcomes..
65.
2013
-
Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium..
65.
2013
-
Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time..
66.
2013
-
Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool..
65.
2013
-
Should antibiotics be given prior to outpatient cystoscopy? A plea to urologists to practice antibiotic stewardship..
65.
2013
-
Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality..
65.
2013
-
Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder..
65.
2013
-
Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance..
66.
2013
-
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival..
65.
2013
-
Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus..
66.
2013
-
Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool..
66.
2013
-
Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam..
64.
2013
-
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy..
65.
2013
-
Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy..
64.
2013
-
A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy..
64.
2013
-
Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen..
65.
2013
-
Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity..
64.
2013
-
Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium..
64.
2013
-
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality..
63.
2012
-
Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy..
64.
2012
-
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials..
63.
2012
-
Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma..
63.
2012
-
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial..
64.
2012
-
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma..
63.
2012
-
In-hospital mortality and failure to rescue after cytoreductive nephrectomy..
63.
2012
-
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity..
63.
2012
-
Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer..
63.
2012
-
Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients..
63.
2012
-
Robotic intracorporeal orthotopic ileal neobladder: replicating open surgical principles..
62.
2012
-
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer..
63.
2012
-
Effect of a risk-stratified grade of nerve-sparing technique on early return of continence after robot-assisted laparoscopic radical prostatectomy..
63.
2012
-
Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis..
64.
2012
-
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay..
63.
2012
-
Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project)..
64.
2012
-
Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy..
63.
2012
-
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy..
63.
2012
-
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid..
65.
2012
-
Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma..
65.
2012
-
Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy..
62.
2012
-
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial..
62.
2012
-
Robotic transrectal ultrasonography during robot-assisted radical prostatectomy..
62.
2012
-
Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis..
62.
2012
-
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample..
61.
2012
-
Technical refinement and learning curve for attenuating neurapraxia during robotic-assisted radical prostatectomy to improve sexual function..
61.
2012
-
Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery..
62.
2012
-
Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity..
61.
2012
-
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism..
61.
2012
-
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index..
62.
2012
-
Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification..
62.
2012
-
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma..
61.
2012
-
Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study..
61.
2012
-
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial..
61.
2012
-
Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample..
61.
2011
-
Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series..
61.
2011
-
Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: results from the 100% Medicare sample..
61.
2011
-
A non-cancer-related survival benefit is associated with partial nephrectomy..
61.
2011
-
180-W XPS GreenLight laser therapy for benign prostate hyperplasia: early safety, efficacy, and perioperative outcome after 201 procedures..
61.
2011
-
Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters..
61.
2011
-
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men..
61.
2011
-
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment..
61.
2011
-
The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy..
61.
2011
-
Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study..
61.
2011
-
Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes..
60.
2011
-
Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy..
60.
2011
-
A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis..
60.
2011
-
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate..
60.
2011
-
Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort..
60.
2011
-
The surgical learning curve for artificial urinary sphincter procedures compared to typical surgeon experience..
60.
2011
-
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response..
60.
2011
-
Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes..
60.
2011
-
Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer..
60.
2011
-
Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer..
59.
2011
-
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration..
60.
2011
-
The impact of prostate size, median lobe, and prior benign prostatic hyperplasia intervention on robot-assisted laparoscopic prostatectomy: technique and outcomes..
59.
2011
-
Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement..
60.
2011
-
The prognostic significance of capsular incision into tumor during radical prostatectomy..
59.
2010
-
Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center..
59.
2010
-
Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis..
59.
2010
-
A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006..
59.
2010
-
Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension..
59.
2010
-
Athermal division and selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy: description of technique and outcomes..
59.
2010
-
Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?.
58.
2010
-
Randomized controlled trial of barbed polyglyconate versus polyglactin suture for robot-assisted laparoscopic prostatectomy anastomosis: technique and outcomes..
58.
2010
-
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center..
58.
2010
-
Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy..
58.
2010
-
Recovery of renal function after open and laparoscopic partial nephrectomy..
58.
2010
-
GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up..
58.
2010
-
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome..
58.
2010
-
Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study..
57.
2010
-
Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study..
57.
2009
-
Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy..
57.
2009
-
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract..
57.
2009
-
Anatomic bladder neck preservation during robotic-assisted laparoscopic radical prostatectomy: description of technique and outcomes..
56.
2009
-
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort..
57.
2009
-
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort..
56.
2009
-
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer..
56.
2009
-
Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy..
57.
2009
-
A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma..
56.
2009
-
The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?.
56.
2009
-
A comparison of postoperative complications in open versus robotic cystectomy..
57.
2009
-
CEACAM1: a novel urinary marker for bladder cancer detection..
57.
2009
-
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases..
56.
2009
-
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer..
56.
2009
-
Comparative assessment of antimicrobial activities of antibiotic-treated penile prostheses..
56.
2008
-
Thirty-day mortality after nephrectomy: clinical implications for informed consent..
56.
2008
-
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience..
55.
2008
-
Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer..
55.
2008
-
Recovery of urinary continence after radical prostatectomy: association with urethral length and urethral fibrosis measured by preoperative and postoperative endorectal magnetic resonance imaging..
55.
2008
-
Re: lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC..
54.
2008
-
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology..
55.
2008
-
Oncologic outcome and patterns of recurrence after salvage radical prostatectomy..
55.
2008
-
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience..
55.
2008
-
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients..
55.
2008
-
Hydrogen sulphide is involved in testosterone vascular effect..
56.
2008
-
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique..
53.
2008
-
Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer..
53.
2007
-
Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer..
54.
2007
-
High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer..
54.
2007
-
Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men..
54.
2007
-
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy..
53.
2007
-
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy..
53.
2007
-
Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy..
53.
2007
-
Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group..
53.
2007
-
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium..
52.
2007
-
Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy..
52.
2007
-
Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy..
52.
2007
-
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction..
51.
2007
-
Development and validation of a premature ejaculation diagnostic tool..
52.
2007
-
Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy..
52.
2006
-
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL..
52.
2006
-
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy..
51.
2006
-
Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer..
51.
2006
-
The natural history of noncastrate metastatic prostate cancer after radical prostatectomy..
51.
2006
-
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy..
51.
2006
-
Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy..
51.
2006
-
Precystectomy nomogram for prediction of advanced bladder cancer stage..
50.
2006
-
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy..
51.
2006
-
Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy..
49.
2006
-
Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml..
49.
2005
-
Positive surgical margins and accessory pudendal artery preservation during laparoscopic radical prostatectomy..
48.
2005
-
Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder..
48.
2005
-
Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder..
48.
2005
-
Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology..
45.
2004
-
A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder..
44.
2003
-
Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index?.
42.
2002
-
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients..
39.
2001
-
Detrusor contraction duration may predict response to alpha-blocker therapy for lower urinary tract symptoms..
37.
2000
-
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group..
36.
1999
-
Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer..
35.
1999
-
Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis..
32.
1997
-
The antiandrogen withdrawal syndrome in relapsed prostate cancer..
31 Suppl 2.
1997
-
Tissue polypeptide-specific antigen in renal cell carcinoma..
30.
1996
-
Proscar: five-year experience..
28.
1995
-
5 alpha-reductase deficiency: human and animal models..
25 Suppl 1.
1994
-
5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review..
20 Suppl 1.
1991
-
Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival..
19.
1991
-
Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors..
19.
1991
-
Antigen expression in renal cell carcinoma. Correlation with histological grade, pathological stage and development of distant metastasis..
18 Suppl 2.
1990
-
Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy..
18 Suppl 2.
1990
-
Chemotherapeutic management of invasive bladder carcinoma..
14 Suppl 1.
1988
-
Chemotherapy and cystectomy in patients with bladder carcinoma..
14 Suppl 1.
1988
-
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]..
83.
2023
-
Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]..
82.
2022
-
Corrigendum re "Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review" [Eur Urol 2021;79:330-3]..
79.
2021
-
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]..
79.
2021
-
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]..
78.
2020
-
Corrigendum re: "effect of a risk-stratified grade of nerve-sparing technique on early return of continence after robot-assisted laparoscopic radical prostatectomy" [Eur Urol 2013;63:438-44]..
68.
2015
-
Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]..
68.
2015
-
Corrigendum to "Focal Therapy for Prostate Cancer: Possibilities and Limitations" [Eur Urol 2010;58:57-64]..
58.
2010
-
Prostate cancer chemotherapy. Interview by Christine McKillop..
51.
2007
-
Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer.
2020
-
Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.
2020
-
Re: The Effect of Antioxidants on Male Factor Infertility: The Males, Antioxidants, and Infertility (MOXI) Randomized Clinical Trial.
2020
-
Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
2020
-
Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
2019
-
Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study.
2019
-
Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
2018
-
Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
2017
-
Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
2017
-
Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
2017
-
Re: Lower Urinary Tract Symptoms and Incident Falls in Community Dwelling Older Men: The Concord Health and Ageing in Men Project.
2017
-
Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial.
2016
-
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
2016
-
Re: Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-based Approach.
2016
-
Re: Failure-Free Survival and Radiotherapy in Patients with Newly Diagnosed Nonmetastatic Prostate Cancer: Data from Patients in the Control Arm of the STAMPEDE Trial.
2016
-
Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
2016
-
Words of Wisdom. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
2016
-
Re: nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.
2015
-
Words of Wisdom. Re: Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
2015
-
Words of wisdom. Re: Testosterone treatment is a potent tumor promoter for the rat prostate.
2015
-
Re: whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.
2015
-
Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review.
2014
-
Word of wisdom. Re: effect of rejuvenation hormones on spermatogenesis.
2014
-
Words of wisdom. Re: radical prostatectomy or watchful waiting in early prostate cancer.
2014
-
Re: Global effects of smoking, of quitting, and of taxing tobacco.
2014
-
Predictors of cancer-specific mortality after disease recurrence in patients with squamous cell carcinoma of the penis.
2014
-
The lethal clone in prostate cancer: redefining the index.
2014
-
Words of wisdom: Re: Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group trial.
2013
-
Words of wisdom. Re: Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
2013
-
Words of wisdom. Re: Radical prostatectomy versus observation for localized prostate cancer.
2013
-
Reply from authors re: Manfred P. Wirth, Johannes Huber. What really matters is rarely measured: outcome of routine care and patient-reported outcomes. Eur Urol 2013;64:58-9: robot-assisted versus open radical cystectomy: beating a dead horse.
2013
-
Words of wisdom: re: a prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.
2013
-
Words of wisdom. Re: antioxidants for male subfertility.
2012
-
Words of wisdom. Re: Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
2012
-
Words of wisdom: Re: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.
2011
-
Words of wisdom. Re: Testicular spermatozoa have statistically significantly lower DNA damage compared with ejaculated spermatozoa in patients with unsuccessful oral antioxidant treatment.
2011
-
Words of Wisdom. Re: use of radical cystectomy for patients with invasive bladder cancer.
2011
-
Words of wisdom. Re: Comparative effectiveness of minimally invasive vs open radical prostatectomy.
2010
-
Words of wisdom. Re: Rethinking screening for breast cancer and prostate cancer.
2010
-
Words of wisdom. Re: Fertility preservation in adolescent males: experience over 22 years at Rouen University Hospital.
2010
-
Words of wisdom. Re: Outcome after radical cystectomy with limited or extended pelvic lymph node dissection.
2010
-
Words of wisdom. Re: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V.
2009
-
Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81.
2009
-
Words of wisdom. Re: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. J Urol 2008;179:1830-7; discussion 1837.
2009
-
Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators.
2008
-
Words of wisdom. Re: Persistent motile sperm after ligation band vasectomy.
2007
-
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.
2023
-
Reply to Carlos Gustavo Trujillo, Sebastián Peña Rodríguez, and Cesar Díaz Ritter's Letter to the Editor re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol 2023;83:534-47.
2023
-
Industry Payments to American Editorial Board Members for Major Urology Journals.
2023
-
Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.
2021
-
Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
2021
-
Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016.
2020
-
Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen.
2020
-
The Impact of COVID-19 Outbreak on Uro-oncological Practice Across Europe: Which Burden of Activity Are We Facing Ahead?
2020
-
A Plea for the Evaluation of the Carbon Footprint of New Mini-invasive Surgical Technologies in Urology.
2020
-
Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?
2019
-
Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28: Radiation Therapy Versus Radical Prostatectomy: No Way Out Without a Randomized Trial.
2018
-
Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28.
2018
-
Prevalence of and Risk Factors for Urinary Incontinence in Home Hospice Patients.
2018
-
Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
2018
-
Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer.
2018
-
Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8.
2017
-
Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens.
2017
-
Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol 2017;72:177-88.
2017
-
Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042.
2017
-
Reply to Thorsten Derlin, Christoph-A. von Klot, and Katja Hueper's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042.
2017
-
Re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61.
2016
-
Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61.
2016
-
Reply to Filippo Alongi, Rosario Mazzola, Dario Aiello and Matteo Salgarello's Letter to the Editor re: Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37-43. A Step Forward in the Era of Functional Imaging?: Functional Imaging and Micrometastatic Disease: Implications for Radiotherapy Field Design.
2016
-
Does Low-value Care Affect Urologists?
2016
-
Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States.
2016
-
Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis.
2016
-
Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40.
2016
-
Reply to Gianluca Giannarini, Alessandro Crestani, Andrea Porzionato, Veronica Macchi, and Vincenzo Ficarra's Letter to the Editor re: Massimiliano Spaliviero, Bing Ying Poon, Christoph A. Karlo, et al. An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. Eur Urol 2016;69:72-9.
2015
-
Reply to Marco Borghesi, Gaetano La Manna, and Riccardo Schiavina's Letter to the Editor re: Sabine D. Brookman-May, Matthias May, Ingmar Wolff, et al. Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1-pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA Project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors? Eur Urol 2015;67:943-51.
2015
-
Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038.
2015
-
Reply to Farshad Pourmalek, Hamidreza Abdi, and Peter C. Black's Letter to the Editor re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. Eur Urol 2015;68:399-405.
2015
-
Reply to Michael Froehner, Manfred P. Wirth's letter to the editor re: Jim C. Hu, Giorgio Gandaglia, Pierre I. Karakiewicz, et al. Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control. Eur Urol 2014;66:666-72.
2014
-
Reply to Michael Froehner, Rainer Koch, and Manfred P. Wirth's letter to the editor re: Karim A. Touijer, Clarisse R. Mazzola, Daniel D. Sjoberg, Peter T. Scardino, James A. Eastham. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 2014;65:20-5.
2013
-
Reply to Donald L. Lamm and Nilay M. Gandhi's letter to the editor re: Behfar Ehdaie, Richard Sylvester, Harry W. Herr. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85.
2013
-
Words of wisdom: Re: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms.
2013
-
Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
2013
-
Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.
2013
-
Re: Alberto Briganti, Thomas Wiegel, Steven Joniau, et al. early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 2012;62:472-87: statistical concerns with Briganti radiotherapy analysis.
2013
-
Oncologic outcomes and survival in pT0 tumors after radical nephroureterectomy for upper tract urothelial carcinoma: results from of a large multicenter international collaborative study.
2012
-
Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer.
2012
-
Collaborative research networks as a platform for virtual multidisciplinary, international approach to managing difficult clinical cases: an example from the Upper Tract Urothelial Carcinoma Collaboration.
2012
-
High-resolution magnetic resonance imaging of prostatectomy specimens: a promising tool for virtual histology.
2012
-
Uptake of laparoscopic radical nephroureterectomy in France: a 2003-2011 national practice report.
2012
-
Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy.
2012
-
Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma.
2012
-
Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence.
2012
-
Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma.
2012
-
Does low-risk prostate cancer detection change with repeat biopsies?
2011
-
Stage pT0 after radical cystectomy: are all patients equal?
2011
-
Challenges of interpreting and improving radical prostatectomy outcomes: technique, technology, training, and tactical reporting.
2011
-
Important considerations in the clinical use of preoperative prostate cancer predictive nomograms.
2010
-
Re: Derya Tilki, Oliver Reich, Pierre I. Karakiewicz, et al. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol 2010;58:112-7.
2010
-
Why I perform robotic-assisted laparoscopic radical prostatectomy, despite more incontinence and erectile dysfunction diagnoses compared to open surgery: it's not about the robot.
2009
-
Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder.
2009
-
Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy--results from a multicenter study.
2008
-
Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best.
2008
-
Re: Francesco Montorsi. A plea for integrating laparoscopy and robotic surgery in everyday urology: the rules of the game. Eur urol 2007;52:307-9.
2007
-
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
2022
-
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
2020
-
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.
2019
-
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
2017
-
Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel.
2015
-
Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.
2014
-
Focal therapy in prostate cancer: international multidisciplinary consensus on trial design.
2014
-
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group.
2013
-
ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology.
2012
-
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers.
2012
-
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
2012
-
ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate.
2012
-
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel.
2012
-
Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines.
2023
-
Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022..
84.
2023
-
Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer..
82.
2022
-
Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review..
79.
2020
-
Clinical Impact and Statistical Significance of Multiparametric Magnetic Resonance Imaging for Local Staging of Prostate Cancer..
79.
2020
-
Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation..
79.
2020
-
CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?.
78.
2020
-
Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer..
77.
2020
-
Docetaxel for Early Prostate Cancer: What Have We Learned?.
77.
2020
-
Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?.
77.
2019
-
The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data..
76.
2019
-
Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails..
77.
2019
-
Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol 2019;76:413-5: Two Decades of World Health Organisation/International Society of Urological Pathology Bladder Cancer Grading: Time to Reflect on Accomplishments and Plan Refinement in the Molecular Era, Not Regress to Readoption of a 45-year-old Classification..
76.
2019
-
Anticholinergic Burden in the Elderly Population: An Emerging Concern..
76.
2019
-
Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility..
76.
2019
-
Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome..
73.
2017
-
Anything New for Nocturia?.
72.
2017
-
Electronic Cigarettes: A Wolf in Sheep's Clothing..
71.
2017
-
Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions..
71.
2016
-
Improving Survival for Metastatic Castrate-resistant Prostate Cancer: Will Combination Therapy Help Us To Move Forward?.
70.
2016
-
The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer..
70.
2016
-
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia..
69.
2015
-
A "Chicken or Egg" Conundrum: Race, Molecular Subtype, and Tumor Location in Prostate Cancer..
70.
2015
-
Reply from Authors re: Alexandre Mottrie, Giorgio Gandaglia. Do We Need a Novel Nephrometry Scoring System in Partial Nephrectomy? Eur Urol 2016;69:80-1: Nephrometry Scores for Partial Nephrectomy: The Importance of Defining a Context of Use..
69.
2015
-
The Tale of Two Hypoxia-Inducible Factors in Renal Cell Carcinoma..
69.
2015
-
Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use..
69.
2015
-
How Should the Prevalence of Urinary Incontinence Be Determined in a Female Population?.
69.
2015
-
The prostatic urethral lift procedure: enough bang for the buck?.
68.
2015
-
Observed Advantages of the STAMPEDE Study Design..
67.
2014
-
Standardization of patient-centered outcomes: less is more..
67.
2014
-
Understanding long-term urinary adverse events after treatment of localized prostate cancer: a key tool in informed decision-making..
67.
2014
-
European Urology: serving our readership through systematic peer review, use of reporting standards, and encouragement of postpublication review..
67.
2014
-
Reply from Author re: Peter C. Black. Narrowing the cystoscopy gap. Eur Urol 2015;67:609-10: A better transurethral resection--proved or not!.
67.
2014
-
To clamp or not to clamp the main renal artery: the debate continues..
66.
2014
-
Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer..
66.
2014
-
It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening..
66.
2014
-
Predicting biochemical recurrence following salvage radiotherapy: applying lessons learned from primary radiotherapy..
66.
2014
-
Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?.
65.
2013
-
What are the implications of the surgical learning curve?.
65.
2013
-
Reply from authors re: Arthur L. Burnett. Erection rehabilitation after radical prostatectomy: definite purpose, indefinite strategy. Eur Urol 2014;65:597-8: although erection rehabilitation after prostatectomy remains indefinite, the most effective treatment, the earliest recovery, and the preservation of erectile function remain a definite goal..
65.
2013
-
Application of the IDEAL framework to robotic urologic surgery..
65.
2013
-
Molecular characterization of prostate cancer following androgen deprivation: the devil in the details..
66.
2013
-
Magnetic resonance imaging-targeted prostate biopsies: now is the time to START..
64.
2013
-
Improved survival with surgery in prostate cancer patients without medical comorbidity: a self-fulfilling prophecy?.
64.
2013
-
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial..
64.
2013
-
Effective management of localized prostate cancer: first, do no harm..
64.
2013
-
Identifying an ERG-positive subclass with clinical progression using expression profiling..
64.
2013
-
Oncologic outcomes achieved by radical cystectomy..
64.
2013
-
Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility..
64.
2013
-
Renal cancer therapy: going forward by going backward?.
63.
2013
-
Lower urinary tract symptoms, benign prostatic hyperplasia, and prostate cancer: seek and ye shall find..
63.
2013
-
5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice..
63.
2013
-
Artificial urinary sphincter: the workhorse for treatment of male stress urinary incontinence..
63.
2012
-
The changing face of renal cell carcinoma: the impact of systematic genetic sequencing on our understanding of this tumor's biology..
63.
2012
-
Reply from Authors re: Declan G. Murphy, Anthony J. Costello. How Can the Autonomic Nervous System Contribute to Urinary Continence Following Radical Prostatectomy? A "Boson-like" Conundrum. Eur Urol 2013;63:445-7: Sparing of the Neurovascular Bundle Leads to Improved Rates of Continence..
63.
2012
-
The promise and challenges of randomized controlled trials for surgical interventions..
63.
2012
-
Technical advances in bladder cancer patient care: progress or promise?.
62.
2012
-
Magnetic resonance imaging-targeted prostate biopsy: back to the future..
63.
2012
-
Is radiofrequency ablation for small kidney tumors ready for prime time?.
61.
2012
-
Robotic prostatectomy: the rise of the machines or judgment day..
61.
2012
-
PSA is dead, long live PSA..
61.
2011
-
Laparoendoscopic single-site surgery for the upper urinary tract: awaiting evidence..
61.
2011
-
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy..
61.
2011
-
Can we apply nomograms derived in the United States to European patients? Yes, we can!.
61.
2011
-
The devil is in the details..
59.
2011
-
The use of 5α-reductase inhibitors for the prevention and treatment of prostate cancer..
59.
2011
-
Deleterious renal functional outcomes after radical nephrectomy..
59.
2010
-
Marketing versus science: a fight between necessary evil and stern good over the adoption of new technology in medicine..
58.
2010
-
Prediction models in urology: are they any good, and how would we know anyway?.
57.
2009
-
Prognostication of upper tract urothelial carcinoma: what do we really need?.
57.
2009
-
Extent of pelvic lymph node dissection during radical cystectomy: where and why!.
57.
2009
-
Editorial comment on: oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures..
57.
2009
-
Editorial comment on: The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?.
56.
2009
-
Editorial comment on: detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience..
57.
2009
-
Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?.
56.
2009
-
Editorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery..
57.
2009
-
Editorial comment on: Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan..
55.
2009
-
Perioperative intravesical therapy: effective treatment, unfulfilled promises..
55.
2009
-
Is metastasectomy for urothelial carcinoma worthwhile?.
55.
2008
-
Editorial comment on: Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: surgical technique and experience with the first 99 cases..
55.
2008
-
Neoadjuvant chemotherapy: a new treatment paradigm for muscle-invasive bladder cancer..
55.
2008
-
Predictive modeling in prostate cancer: a conference summary..
55.
2008
-
Editorial comment on: External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients..
56.
2008
-
Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy..
55.
2008
-
Editorial comment on: Prognosis value of renal vein and inferior vena cava involvement in renal cell carcinoma..
55.
2008
-
Robotic-assisted prostatectomy: is there truth in advertising?.
54.
2008
-
The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective..
54.
2008
-
Editorial comment on: Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience..
55.
2008
-
Is maintenance Bacillus Calmette-Guérin really necessary?.
54.
2008
-
Editorial comment on: MR-guided biopsy of the prostate: an overview of techniques and a systematic review..
54.
2008
-
Editorial comment on: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker..
56.
2008
-
Editorial comment on: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer..
54.
2008
-
Editorial comment on: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer..
54.
2008
-
Editorial comment on: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy..
55.
2008
-
Editorial comment on: robotic-assisted laparoscopic radical cystectomy with extracorporeal urinary diversion: initial experience..
54.
2008
-
Editorial comment on: preservation of renal function following partial or radical nephrectomy using 24-hour creatinine clearance..
54.
2008
-
Rebuttal from authors re: James W.F. Catto. More nomograms or better evidence of efficacy: what do we need in urologic oncology? Eur Urol 2008;54:11-12..
54.
2008
-
Editorial comment on: Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries..
56.
2008
-
Perspectives on prostate cancer biomarkers..
54.
2008
-
Rebuttal from author re: Axel Heidenreich. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ preserving therapy in carefully selected patients. Eur Urol 2008;54:21-23..
54.
2008
-
The search for better prognostic factors for men treated for localized prostate cancer continues..
53.
2007
-
Screening for prostate cancer in 2007: the PSA era and its challenges are not over..
53.
2007
-
Editorial comment on: first analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer..
53.
2007
-
Editorial comment on: Robotic partial nephrectomy for complex renal tumors: surgical technique..
53.
2007
-
How many lymphadenectomies does it take to cure one patient?.
53.
2007
-
Detection and management of isolated lymph node recurrence in patients with PSA relapse..
52.
2007
-
Should we abandon the FISH test?.
51.
2007
-
Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms..
51.
2007
-
Urinary continence after radical prostatectomy: "beauty is in the eye of the beholder"..
51.
2006
-
Management of Lymph Node-positive Penile Cancer: A Systematic Review.
2023
-
Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis.
2023
-
European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update.
2023
-
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
2022
-
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
2021
-
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
2021
-
Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.
2021
-
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
2021
-
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
2020
-
Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
2020
-
Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis.
2019
-
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
2019
-
Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.
2019
-
Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.
2018
-
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
2018
-
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
2018
-
Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
2018
-
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
2018
-
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.
2017
-
Recommendations for the Management of Rare Kidney Cancers.
2017
-
Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review.
2017
-
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
2017
-
Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.
2017
-
Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
2017
-
Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis.
2017
-
Pathophysiology and Contributing Factors in Postprostatectomy Incontinence: A Review.
2016
-
Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.
2016
-
DNA Repair in Prostate Cancer: Biology and Clinical Implications.
2016
-
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
2016
-
Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
2016
-
Preoperative Membranous Urethral Length Measurement and Continence Recovery Following Radical Prostatectomy: A Systematic Review and Meta-analysis.
2016
-
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.
2016
-
Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs.
2016
-
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
2016
-
Testosterone Therapy in Men With Prostate Cancer.
2015
-
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.
2015
-
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
2015
-
A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy.
2015
-
Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.
2015
-
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.
2015
-
Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature.
2015
-
Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy.
2015
-
A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma.
2014
-
Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review.
2014
-
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
2014
-
Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.
2014
-
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
2014
-
The economics of bladder cancer: costs and considerations of caring for this disease.
2014
-
A review of the current status of laparoscopic and robot-assisted sacrocolpopexy for pelvic organ prolapse.
2014
-
Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making.
2013
-
Early salvage radiotherapy following radical prostatectomy.
2013
-
Positive surgical margins after radical prostatectomy: a systematic review and contemporary update.
2013
-
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
2013
-
Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature.
2013
-
The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
2013
-
Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence.
2013
-
The mutational landscape of prostate cancer.
2013
-
The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review.
2013
-
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature.
2013
-
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
2013
-
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms.
2013
-
Lymphadenectomy for bladder cancer at the time of radical cystectomy.
2013
-
A systematic review of the volume-outcome relationship for radical prostatectomy.
2013
-
Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature.
2013
-
Timing of curative treatment for prostate cancer: a systematic review.
2013
-
Screening for bladder cancer: rationale, limitations, whom to target, and perspectives.
2013
-
A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens.
2012
-
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care.
2012
-
Costs of radical prostatectomy for prostate cancer: a systematic review.
2012
-
Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
2012
-
Epidemiology and risk factors of urothelial bladder cancer.
2012
-
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy.
2012
-
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy.
2012
-
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
2012
-
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy.
2012
-
Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.
2012
-
A review of integrated staging systems for renal cell carcinoma.
2012
-
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature.
2012
-
High-risk prostate cancer: from definition to contemporary management.
2012
-
Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature.
2012
-
Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
2012
-
Novel molecular targets for the therapy of castration-resistant prostate cancer.
2011
-
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.
2011
-
Risk-based prostate cancer screening.
2011
-
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.
2011
-
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
2011
-
Lymph node dissection in renal cell carcinoma.
2011
-
Contemporary role of androgen deprivation therapy for prostate cancer.
2011
-
Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer.
2011
-
Current pathology keys of renal cell carcinoma.
2011
-
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.
2011
-
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
2011
-
Epigenetics in prostate cancer: biologic and clinical relevance.
2011
-
Sequelae of treatment in long-term survivors of testis cancer.
2011
-
Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
2011
-
The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications.
2011
-
New therapies for castration-resistant prostate cancer: efficacy and safety.
2011
-
The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
2011
-
Contemporary management of postprostatectomy incontinence.
2011
-
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer.
2011
-
Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy.
2011
-
Toxicities of targeted therapy and their management in kidney cancer.
2011
-
Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature.
2010
-
Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.
2010
-
A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution?
2010
-
Focal therapy for prostate cancer: possibilities and limitations.
2010
-
A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy.
2009
-
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications.
2009
-
Metastatic renal cell carcinoma: recent advances in the targeted therapy era.
2009
-
Assessing the impact of ischaemia time during partial nephrectomy.
2009
-
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.
2009
-
Complications following radical cystectomy for bladder cancer in the elderly.
2009
-
Pelvic lymph node dissection in prostate cancer.
2009
-
Functional magnetic resonance imaging in prostate cancer.
2009
-
Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer.
2008
-
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.
2008
-
Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences.
2008
-
Nomograms for bladder cancer.
2008
-
Challenges of cancer biomarker profiling.
2007
-
Current indications for chemotherapy in prostate cancer patients.
2006
-
Laparoscopic radical prostatectomy: a critical analysis of surgical quality.
2006
-
Free/total prostate-specific antigen ratio--hope and controversies.
1997
-
Molecular events in the early phases of prostate carcinogenesis.
1996
-
Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for.
1996
-
Current controversies in the management of localized prostate cancer.
1995
-
Chemotherapy of germ cell tumors: current status and future directions.
1993
-
Prognostic factors for metastatic testicular germ cell tumours: the Memorial Sloan-Kettering cancer model.
1993
-
pT1 bladder cancer.
1991
-
Monoclonal antibodies to renal cancer antigens.
1990
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)